Relative effects of immunohistochemical expressions of c-erbB-2, p53, and bcl-2 oncoproteins on the survival of advanced breast cancer patients after endocrine therapy

International Journal of Oncology

Volumn 9, Issue 1, 1996, Pages 131-136

  Osaki, Akihiko ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

advanced breast cancer; bcl 2; c erbB 2; endocrine therapy; immunohistochemical expression; p53; response; survival

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029939561     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.1.131     Document Type: Article

References (4)

1. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M and Henderson IC: c-erbR-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994.
2. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
3. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
4. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM and Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenie growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1992.